Raymond L. Woosley, MD, PhD
Dr. Woosley earned a Ph.D. in Pharmacology from the University of Louisville (1967) and an M.D. degree from the University of Miami (1971).
completed Post-doctoral training at the University of Louisville
in Pharmacology and at Vanderbilt University
in Clinical Pharmacology.
Following graduate school, he served as the first scientist employed by Meyer Laboratories (now GSK, Inc.). After returning to study medicine, he graduated from the University of Miami School of Medicine and then specialized in Internal Medicine and Clinical Pharmacology at Vanderbilt University.
remained on the faculty and rose to the rank of Professor of Medicine and Pharmacology.
From 1988 to 2001, he was Chairman of the Department of Pharmacology at Georgetown University.
In 2001 he assumed the position of Associate Dean for Clinical Research.
From 2001 to 2005 he was Vice President for Health Sciences at The University of Arizona.
From 2005 to 2012 he was President and CEO of The Critical Path Institute.
In 2012, he founded the not-for-profit AZCERT and serves as President and Chairman of the Board of Directors.
He has served on many national advisory committees for the NIH, Veterans Administration, the US Pharmacopeial Convention, the Cardiorenal Advisory Committee of the Food and Drug Administration, the Institute of Medicine (National Academy of Sciences) and chairman of the Joint Advisory Committee on Cardiovascular Drugs for the American Heart Association and the American College of Cardiology.
He has served as ad hoc consultant for numerous FDA advisory committees, a Special Consultant for the FDA, and a member of the Director's Advisory Committee on Clinical Research for the NIH's National Center for Research Resources.
Dr. Woosley's research
has investigated the basic and clinical pharmacology of antiarrhythmic drugs and he
is considered an international authority on the drug treatment of arrhythmias.
has demonstrated the importance of active drug metabolites, stereoisomerism and pharmacogenetic differences in drug metabolism as factors influencing the pharmacologic and clinical response to antiarrhythmic drugs, beta adrenergic antagonists, antimalarials and antihistamines such as terfenadine.
research has identified the mechanisms responsible for the greater risk of drug-induced arrhythmias in women.
research has been reported in over 300 publications including 185 original articles, 50 book chapters and 60 invited reviews.
In March of 1990, he
received the Rawls-Palmer Award for his
contributions to medicine by the American Society of Clinical Pharmacology and Therapeutics
In 2001, he
received the Henry Gold Award from the Society.
was selected by practicing physicians to be listed in The Best Doctors in America from 1994-2000.